Dalcetrapib

Drug Profile

Dalcetrapib

Alternative Names: JTT-705; R 1658; RG1658; RO 4607381

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Japan Tobacco
  • Developer DalCor Pharmaceuticals; Japan Tobacco; Montreal Heart Institute; Roche
  • Class Antihyperlipidaemics; Cyclohexanes; Small molecules; Thioesters
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute coronary syndromes
  • Discontinued Atherosclerosis; Coronary disorders; Hyperlipidaemia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 18 Jul 2016 Pharmacodynamics data from the phase III dal-OUTCOMES trial in Acute coronary syndromes released by DalCor Pharmaceuticals
  • 26 Apr 2016 Phase-III clinical trials in Acute coronary syndromes in Canada (PO) (NCT02525939)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top